{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:55:05Z","timestamp":1791899705494,"version":"4.3.4"},"reference-count":24,"publisher":"BMJ","issue":"8","license":[{"start":{"date-parts":[[2024,8,21]],"date-time":"2024-08-21T00:00:00Z","timestamp":1724198400000},"content-version":"unspecified","delay-in-days":20,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001922","name":"Efficacy and Mechanism Evaluation Programme","doi-asserted-by":"publisher","award":["17\/60\/51"],"award-info":[{"award-number":["17\/60\/51"]}],"id":[{"id":"10.13039\/501100001922","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013342","name":"NIHR Imperial Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013342","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2024,8,5]]},"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>A minority of school-aged children with asthma have persistent poor control and experience frequent asthma attacks despite maximal prescribed maintenance therapy. These children have higher morbidity and risk of death. The first add-on biologic therapy, omalizumab, a monoclonal antibody that blocks immunoglobulin (Ig)E, was licensed for children with severe asthma in 2005. While omalizumab is an effective treatment, non-response is common. A second biologic, mepolizumab which blocks interleukin 5 and targets eosinophilic inflammation, was licensed in 2018, but the licence was granted by extrapolation of adult clinical trial data to children. This non-inferiority (NI) trial will determine whether mepolizumab is as efficacious as omalizumab in reducing asthma attacks in children with severe therapy resistant asthma (STRA) and refractory difficult asthma (DA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>This is an ongoing multicentre 1:1 randomised NI open-label trial of mepolizumab and omalizumab. Up to 150 children and young people (CYP) aged 6\u201317 years with severe asthma will be recruited from specialist paediatric severe asthma centres in the UK. Prior to randomisation, children will be monitored for medication adherence for up to 16 weeks to determine STRA and refractory DA diagnoses. Current prescribing recommendations of serum IgE and blood eosinophils will not influence eligibility or enrolment. The primary outcome is the 52-week asthma attack rate. Bayesian analysis using clinician-elicited prior distributions will be used to calculate the posterior probability that mepolizumab is not inferior to omalizumab. Secondary outcomes include Composite Asthma Severity Index, Paediatric Asthma Quality of Life Questionnaire, lung function measures (forced expiratory volume in one second (FEV1), bronchodilator reversibility), fractional exhaled nitric oxide, Asthma Control Test (ACT), health outcomes EuroQol 5 Dimension (EQ-5D) and optimal serum IgE and blood eosinophil levels that may predict a response to therapy. These outcomes will be analysed in a frequentist framework using longitudinal models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>The study has been approved by the South Central\u2014Berkshire Research Ethics Committee REC Number 19\/SC\/0634 and had Clinical Trials Authorisation from the Medicines and Healthcare Products Regulatory Agency (MHRA) (EudraCT 2019-004085-17). All parents\/legal guardians will give informed consent for their child to participate in the trial, and CYP will give assent to participate. The results will be published in peer-reviewed journals, presented at international conferences and disseminated via our patient and public involvement partners.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"isrctn\" xlink:href=\"ISRCTN12109108\">ISRCTN12109108<\/jats:ext-link>\n                      ; EudraCT Number: 2019-004085-17.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2024-090749","type":"journal-article","created":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T00:50:44Z","timestamp":1724287844000},"page":"e090749","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":8,"title":["Treating severe paediatric asthma with mepolizumab or omalizumab: a protocol for the TREAT randomised non-inferiority trial"],"prefix":"10.1136","volume":"14","clinical-trial-number":[{"clinical-trial-number":"isrctn12109108","registry":"10.18810\/isrctn"}],"author":[{"given":"Victoria","family":"Cornelius","sequence":"first","affiliation":[{"name":"Health and Social Care Research, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daphne","family":"Babalis","sequence":"additional","affiliation":[{"name":"Imperial Clinical Trials Unit, Imperial College London, London, UK"},{"name":"Imperial College London School of Public Health, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William D","family":"Carroll","sequence":"additional","affiliation":[{"name":"Academic Department of Child Health, University Hospitals of North Midlands NHS Trust, Stoke-on-Trent, UK"},{"name":"Institute of Applied Clinical Sciences, Keele University, Keele, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Cunningham","sequence":"additional","affiliation":[{"name":"Department of Child Life and Health, Royal Hospital for Sick Children, Edinburgh, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Fleming","sequence":"additional","affiliation":[{"name":"Royal Brompton Hospital and National Heart & Lung Institute, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erol","family":"Gaillard","sequence":"additional","affiliation":[{"name":"Leicester NIHR Biomedical Research Centre (Respiratory Theme), Leicester, Leicestershire, UK"},{"name":"Paediatric Clinical Investigation Centre, Leicester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul","family":"Gupta","sequence":"additional","affiliation":[{"name":"King\u2019s College Hospital Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Janani","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Kennington","sequence":"additional","affiliation":[{"name":"Asthma and Lung UK, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8961-8055","authenticated-orcid":false,"given":"Clare","family":"Murray","sequence":"additional","affiliation":[{"name":"Division of Immunology, Immunity to Infection and Respiratory Medicine (DIIIRM), School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prasad","family":"Nagakumar","sequence":"additional","affiliation":[{"name":"Institute of Inflammation and Aging, Birmingham Women\u2019s and Children\u2019s Hospitals NHS Foundation Trust, Birmingham, UK"},{"name":"University of Birmingham, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2252-1248","authenticated-orcid":false,"given":"Graham","family":"Roberts","sequence":"additional","affiliation":[{"name":"Human Development and Health Academic Unit, Faculty of Medicine, University of Southampton, Southampton, UK"},{"name":"Respiratory Biomedical Research Unit, Southampton University Hospitals Trust, Southampton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Seddon","sequence":"additional","affiliation":[{"name":"Brighton and Sussex Medical School, Brighton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Sinha","sequence":"additional","affiliation":[{"name":"Faculty of Health and Life Sciences, University of Liverpool, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Streatfield","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise","family":"Weir","sequence":"additional","affiliation":[{"name":"Royal Hospital for Children, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5192-6418","authenticated-orcid":false,"given":"Sejal","family":"Saglani","sequence":"additional","affiliation":[{"name":"National Heart and Lung Institute, Faculty of Medicine, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,8,21]]},"reference":[{"key":"2025121410102921000_14.8.e090749.1","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02130-2018","article-title":"Changing prevalence of current asthma and inhaled corticosteroid treatment inthe UK: population-based cohort 2006-2016","volume":"53","author":"Bloom","year":"2019","journal-title":"Eur Respir J"},{"key":"2025121410102921000_14.8.e090749.2","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1136\/thx.54.4.296","article-title":"Morbidity from asthma in relation to regular treatment: a community based study","volume":"54","author":"Walsh","year":"1999","journal-title":"Thorax"},{"key":"2025121410102921000_14.8.e090749.3","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-016-0657-8","article-title":"The epidemiology, healthcare and societal burden and costs of asthma in the UK and its member nations: analyses of standalone and linked national databases","volume":"14","author":"Mukherjee","year":"2016","journal-title":"BMC Med"},{"key":"2025121410102921000_14.8.e090749.4","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.156.3.9611072"},{"key":"2025121410102921000_14.8.e090749.5","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1183\/20734735.008914","article-title":"The national review of asthma deaths: what did we learn and what needs to change?","volume":"11","author":"Levy","year":"2015","journal-title":"Breathe (Sheff)"},{"key":"2025121410102921000_14.8.e090749.6","unstructured":"National Institute for Health and Care Excellence (NICE) . Asthma: diagnosis and monitoring of asthma in adults, children and young people. London: National Institute for Health and Care Excellence (NICE), 2017."},{"key":"2025121410102921000_14.8.e090749.7","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1586\/1744666X.2015.1083860","article-title":"Omalizumab therapy for children and adolescents with severe allergic asthma","volume":"11","author":"Romano","year":"2015","journal-title":"Expert Rev Clin Immunol"},{"key":"2025121410102921000_14.8.e090749.8","doi-asserted-by":"publisher","DOI":"10.1111\/cea.12853"},{"key":"2025121410102921000_14.8.e090749.9","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/S0140-6736(22)01198-9","article-title":"Mepolizumab for urban children with exacerbation-prone eosinophilic asthma in the USA (MUPPITS-2): a randomised, double-blind, placebo-controlled, parallel-group trial","volume":"400","author":"Jackson","year":"2022","journal-title":"Lancet"},{"key":"2025121410102921000_14.8.e090749.10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60988-X"},{"key":"2025121410102921000_14.8.e090749.11","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00202013"},{"key":"2025121410102921000_14.8.e090749.12","unstructured":"National Institute for Health and Care Excellence, BNF . Omalizumab. Available: https:\/\/bnf.nice.org.uk\/drugs\/omalizumab\/ [Accessed 18 Jun 2024]."},{"key":"2025121410102921000_14.8.e090749.13","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use . Addendum on estimands and sensitivity analysis in clinical trials to the guideline on statistical principles for clinical trials. Available: https:\/\/database.ich.org\/sites\/default\/files\/E9-R1_Step4_Guideline_2019_1203.pdf [Accessed 28 Jun 2024]."},{"key":"2025121410102921000_14.8.e090749.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2011.12.962"},{"key":"2025121410102921000_14.8.e090749.15","first-page":"1905","article-title":"ICH Harmonised Tripartite Guideline. Statistical principles for clinical trials. International Conference on Harmonisation E9 Expert Working Group","volume":"18","year":"1999","journal-title":"Stat Med"},{"key":"2025121410102921000_14.8.e090749.16","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S2213-2600(16)30031-5","article-title":"Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies","volume":"4","author":"Ortega","year":"2016","journal-title":"Lancet Respir Med"},{"key":"2025121410102921000_14.8.e090749.17","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/j.jaci.2017.07.014","article-title":"More than a decade follow-up in patients with severe or difficult-to-treat asthma: The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) II","volume":"141","author":"Chipps","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"2025121410102921000_14.8.e090749.18","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00209511"},{"key":"2025121410102921000_14.8.e090749.19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1001278"},{"key":"2025121410102921000_14.8.e090749.20","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.c332","article-title":"CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials","volume":"340","author":"Schulz","year":"2010","journal-title":"BMJ"},{"key":"2025121410102921000_14.8.e090749.21","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.10.1152"},{"key":"2025121410102921000_14.8.e090749.22","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-017-2248-1","article-title":"Estimating relative risks in multicenter studies with a small number of centers - which methods to use? A simulation study","volume":"18","author":"Pedroza","year":"2017","journal-title":"Trials"},{"key":"2025121410102921000_14.8.e090749.23","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2021-068983","article-title":"Visualising harms in publications of randomised controlled trials: consensus and recommendations","volume":"377","author":"Phillips","year":"2022","journal-title":"BMJ"},{"key":"2025121410102921000_14.8.e090749.24","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2147\/JAA.S129159","article-title":"Managing the pediatric patient with refractory asthma: a multidisciplinary approach","volume":"10","author":"Cook","year":"2017","journal-title":"J Asthma Allergy"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-090749","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T18:10:38Z","timestamp":1765735838000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-090749"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":24,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,8,21]]},"published-print":{"date-parts":[[2024,8]]}},"alternative-id":["10.1136\/bmjopen-2024-090749"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-090749","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8]]}}}